NIKKEI 225
38,961.07 +473.17 (+1.23%) HANG SENG
18,498.33 +418.72 (+2.32%) CRUDE OIL
76.95 -0.04 (-0.05%) GOLD FUTURES
2,341.40 -4.40 (-0.19%) DOW
38,686.32 +574.82 (+1.51%) Bitcoin GBP
53,736.88 +512.64 (+0.96%)
Qiagen N.V. (QIAN.MX)
| Previous close | 757.36 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 784.36 - 784.36 |
| 52-week range | 721.91 - 898.11 |
| Volume | |
| Avg. volume | 536 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | 16.53 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
Next-generation-sequencing-based homologous recombination deficiency (HRD) assay based on QIAGEN’s QIAseq xHYB technology, QIAGEN Digital Insight solutions, and Myriad’s proprietary, FDA-approved MyChoice CDx® biomarkers QIAGEN to make kit-based HRD test available globally to support research and companion diagnostics development in collaboration with pharmaceutical partners enabling wider adoption and potential clinical indication expansion for MyChoice CDx Project builds on recently announced
- Globe Newswire
QIAGEN launches new library preparation kit, facilitating multiomic studies and advancing precision medicine
QIAseq Multimodal DNA/RNA Lib Kit enables streamlined DNA and RNA library preparation for next-generation sequencing from a single sample // New kit advances precision medicine by facilitating multiomic studies and Comprehensive Genomic Profiling, crucial for understanding complex diseases like cancer // Researchers are provided with the first multimodal sequencing kit for multiple sample types, offering high flexibility and sensitivity, saving sample material and timeVenlo, the Netherlands, May
- GlobeNewswire
QIAGEN receives European IVDR certification for QIAGEN Clinical Insight Interpret, its medical device software for clinical decision support
As the first NGS interpretation platform for both oncology and hereditary applications, the updated version of QIAGEN Clinical Insight Interpret is approved for diagnostic use // Regulatory framework ensures greater patient protection, transparency of information, and traceability of data // Over 4 million NGS patient test cases for oncology and hereditary diseases worldwide processed with QIAGEN Clinical Insight InterpretVenlo, the Netherlands, May 14, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGE
